TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

TARGINTA

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

TARGINTA

ST13

US500000079309367

Class

1, 5, 42

Filing

79309367

Registration

6784066

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

33

Latest update

05/08/2026

Classification

Registered

Trademark type

Word

Nice classes

1, 5, 42

Filing date

02/04/2021

Registration date

07/12/2022

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

07/12/2022

Last transaction

05/08/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

99

Owner location

SE

Examiner

REID, CAILE MAUREEN

Law office

N50

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Targinta AB

Representatives

Julie A. Greenberg Reising Ethington P.C.

Technical classification

Nice Classes

Class 1Class 5Class 42

Vienna Codes

No Vienna codes available.

Goods and services

Class 1

Biological preparations for use in industry and science; stem cells for research or scientific purposes; antibodies for research and industrial purposes, namely, Biochemicals in the nature of monoclonal antibodies for in vitro scientific or research use, Laboratory chemicals in the nature of an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use, Diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents to monitor toxicity of drugs; DNA and RNA for scientific and industrial purposes, namely, Test particles for biodetection systems, biological analogues and microscopic carrier beads with chemically attached DNA fragments for use in testing the operation of equipment used for analyzing air for the presence of harmful biological substances, Reagent kits comprising generic DNA circle, DNA primers, polymerase and buffers for use in biotechnology fields, Reagent kit comprising enzyme and chemicals for in vitro transcription of RNA and modified RNA, Gene-based RNA molecular network biomarker reagents for research purposes; proteins for use in science being protein in raw material form for scientific research; chemical test kits, consisting of stem cells, antibodies and proteins, for scientific and industrial purposes for laboratory or research use; reagents for scientific purposes; diagnostic reagents for scientific purposes, not for medical or veterinary purposes; analytical preparations being Chemical buffer and standard solutions used in analytical chemistry, Reagents used for analytical moisture determinations, Reagents for use in scientific apparatus for chemical or biological analysis, Laboratory chemicals in the nature of an antibody reagent used for the detection of antigens in cell and tissue analysis for in vitro diagnostic use, Chemical substances for analyses in laboratories, other than for medical or veterinary purposes for scientific purposes related to cancer treatment and therapies

Class 5

Pharmaceutical and veterinary preparations for the treatment of cancer and for cancer therapies used in the treatment of cancer; stem cells for medical purposes; stem cells for medical and veterinary use; DNA and RNA for medical and veterinary purposes, namely, gene-based RNA molecular network biomarker reagents for medical diagnosis purposes, Medical therapeutic preparations in the nature of biologically active antisense DNA or RNA compounds, Biological products for medical use in recombinant DNA technology in the nature of DNA products allowing recombinant production of polypeptides and monoclonal antibodies; surgical implants grown from stem cells comprising living tissues; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; biological preparations for the treatment of cancer for medical and veterinary purposes; diagnostic kit consisting of stem cells, monoclonal antibodies and proteins for use in disease testing for medical and veterinary purposes; Reagents for medical use, namely, reagents for medical diagnosis and analysis; diagnostic preparations for medical and veterinary use

Class 42

Scientific research; laboratory testing services, namely, scientific research, diagnosis, testing and analysis in the fields of medicine, chemistry, stem cells, RNA, DNA, antibodies and proteins; basic and clinical research in the field of respiratory science and medicine, in particular in relation to the development of medicines; research and development services in the field of diagnostic preparations; quality control for others

Publications

History of USPTO decisions and trademark events.

33 publications found

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

05/06/2026

ARAA

ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED

05/06/2026

REAP

TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED

05/06/2026

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

11/07/2022

FICS

FINAL DISPOSITION NOTICE SENT TO IB

10/19/2022

FIMP

FINAL DISPOSITION PROCESSED

10/19/2022

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/12/2022

NRCC

NOTICE OF REGISTRATION CONFIRMATION EMAILED

07/12/2022

R.PR

REGISTERED-PRINCIPAL REGISTER

07/12/2022

GPNX

NOTIFICATION PROCESSED BY IB

05/03/2022

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/26/2022

PUBO

PUBLISHED FOR OPPOSITION

04/26/2022

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

04/13/2022

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

04/13/2022

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

04/06/2022

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/24/2022

XAEC

EXAMINER'S AMENDMENT ENTERED

03/24/2022

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

03/24/2022

GNEA

EXAMINERS AMENDMENT E-MAILED

03/24/2022

CNEA

EXAMINERS AMENDMENT -WRITTEN

03/24/2022

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

03/16/2022

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

03/15/2022

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

03/15/2022

DOCK

ASSIGNED TO EXAMINER

03/09/2022

RFNT

REFUSAL PROCESSED BY IB

10/25/2021

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

09/27/2021

RFRR

REFUSAL PROCESSED BY MPU

09/27/2021

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

09/10/2021

CNRT

NON-FINAL ACTION WRITTEN

09/09/2021

DOCK

ASSIGNED TO EXAMINER

08/27/2021

MAFR

APPLICATION FILING RECEIPT MAILED

04/27/2021

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

04/23/2021

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

04/22/2021

Continuous trademark protection

Get notified about every new filing that threatens TARGINTA or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.